Company Overview and News

 
Ackman says he supports ADP but puts management on notice

2018-04-17 channelnewsasia
Billionaire investor William Ackman, who lost a proxy contest at Automatic Data Processing last year, said on Tuesday that he wants the human-resources technology company to succeed but said he might be back with a fight if ADP fails to perform.

 
Ackman says he supports ADP but puts management on notice

2018-04-17 reuters
NEW YORK (Reuters) - Billionaire investor William Ackman, who lost a proxy contest at Automatic Data Processing (ADP.O) last year, said on Tuesday that he wants the human-resources technology company to succeed but said he might be back with a fight if ADP fails to perform.

2
Ackman Is Abandoned by Big Pershing Square Investors - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

1
Ackman Vows to End Three Years of Underperformance - Bloomberg

2018-03-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Pershing Square Cashes Out of Nike Stake - WSJ

2018-03-22 wsj
William Ackman’s Pershing Square Capital Management LP cashed out of its brief holding in Nike Inc. NKE -0.74% in recent weeks, for a profit of around $100 million.

 
BRIEF-Pershing Square Releases Regular Weekly Net Asset Value

2018-03-21 reuters
* PERSHING SQUARE HOLDINGS, LTD. RELEASES REGULAR WEEKLY NET ASSET VALUE AS OF 20 MARCH 2018

 
Pershing Square Holdings plans $300 million cash infusion

2018-03-01 reuters
BOSTON (Reuters) - Pershing Square Holdings plans to buy back $300 million worth of its own shares, the company said on Wednesday after Dutch regulators threw up roadblocks that prevented billionaire investor William Ackman from making a tender offer himself.

 
BRIEF-Pershing Square To Launch Tender Offer For Own Shares

2018-02-28 reuters
* PERSHING SQUARE HOLDINGS INTENDS TO LAUNCH TENDER OFFER FOR OWN SHARES FOR $300 MILLION SUBJECT TO SHAREHOLDER VOTE

 
Pershing Square Holdings Intends to Launch Tender Offer for Own Shares for $300 million Subject to Shareholder Vote | Business Wire

2018-02-28 businesswire
Further to the press releases dated 2 and 18 January 2018, Pershing Square Holdings, Ltd. (“PSH”) (LN:PSH) (NA:PSH) today notes the press release of PSCM Acquisition Co LLC ("PSCMAC"), an entity owned by affiliates of Pershing Square Capital Management, L.P. (“PSCM”), in which it announces that it is withdrawing its proposed tender offer for PSH publicly traded shares, as previously announced on 2 January 2018, due to the Dutch Authority for Financial Markets (Autoriteit Financiële Markten, “AFM”) interpretation of certain applicable rules regarding the proposed tender offer, which, in PSCMAC’s view, make the tender offer not feasible.

 
Pershing Square: Going, Going... Will It Be Gone?

2018-02-20 seekingalpha
Pershing Square's total AUM, Pershing Square Capital Management open-end funds plus Pershing Square Holdings, peaked at approximately $20.0 billion in February 2015.

3
Tracking Bill Ackman's Pershing Square Portfolio - Q4 2017 Update

2018-02-15 seekingalpha
The largest three 13F positions are Restaurant Brands International, Automatic Data Processing, and Mondelez International and together they account for ~62% of the portfolio.

 
Chipotle names Taco Bell chief as CEO, to lead turnaround

2018-02-14 in.reuters
(Reuters) - Chipotle Mexican Grill Inc on Tuesday said it had hired Brian Niccol from Yum Brands Inc’s Taco Bell unit as chief executive officer to turn around the burrito chain that has been hurt by a series of food safety lapses.

 
Pershing Square Holdings, Ltd. Announces Directorate Change | Business Wire

2018-02-09 businesswire
Pershing Square Holdings, Ltd. (“PSH”) (LN:PSH) (NA:PSH) announces that Jonathan Kestenbaum has informed the Board of his decision to retire as a non-executive director of the Company due to the increased demands of his executive commitments. Jonathan Kestenbaum has been a non-executive director since 2014. His retirement from the Board will take effect as of 12 February 2018.

 
Pershing Square Holdings, Ltd. Provides Update Regarding Potential Dutch Tender Offer for PSH Shares by Affiliates of Pershing Square Capital Management | Business Wire

2018-01-18 businesswire
Further to the announcements on 3 January and 4 January 2018 (the “Potential Tender Offer Announcements”), the Board of Directors of Pershing Square Holdings, Ltd. (the "Company" or "PSH") (LN:PSH) (NA:PSH) announces that PSCM Acquisition Company LLC (“PSCMAC”) has agreed to increase the price range for its potential Dutch tender offer (the "Potential Tender Offer") for up to $300 million of the Company's public shares (the "Public Shares") from a 24% to 16% discount to net asset value ("NAV") to a revised range of a 16% to 10% discount to NAV.

4
Buy Pershing Square At A 25% Discount To Net Asset Value

2018-01-12 seekingalpha
It is headed by an accomplished star manager who recently got his concentrated portfolio in trouble.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: G7016V101